Led · Equity · Jul 2026

Navi Medical Technologies develops vascular access technologies for neonatal and paediatric care, including its Neonav® ECG Tip Location System that uses real-time intravascular ECG for catheter tip placement and migration surveillance. The Neonav® received US FDA 510(k) clearance in 2025 and an expanded US FDA indication in 2026 covering additional vascular access procedures, giving it broad indications for paediatric and neonatal central venous access. Clinical evaluations of Neonav® have commenced at two leading US children's hospitals. The company has operations in Australia and the United States and plans to begin US commercial sales in 2026. Recent funding will be used to scale manufacturing and build a US commercial team to support hospital launches. Navi positions Neonav® as a tool to enable ongoing catheter position reassessment and reduce repeat imaging in neonatal and paediatric intensive care.

Participated · Series A · Dec 2025

Kitea Health is an Auckland University Bioengineering Institute spin-out building a miniature implant that wirelessly measures pressure inside the brain or heart and transmits data through an external wand. The device is designed to cut down false alarms and provide clinicians with real-time information for patients suffering from hydrocephalus, heart failure, or traumatic injury. Kitea has already completed a first-in-human safety study at Auckland Hospital, implanting the sensor in 20 patients aged 18 months to 84 years with no adverse effects reported. The company is preparing a 150-patient U.S. trial at Texas Children’s Hospital, targeting FDA clearance that could unlock approvals in the UK, Singapore, Australia, and New Zealand. Kitea employs 24 staff (23 in Auckland and one U.S. regulatory specialist) and has attracted $14 million in research grants. Financially, the firm closed an oversubscribed $13 million pre-Series A round, following a $6 million seed raise in 2023, and management believes the new capital will last through late 2027 and completion of U.S. trials. Future capital raises are expected only after trial results, potentially involving U.S. med-tech investors or a strategic acquirer.